We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
KINAXO Extends Collaboration with Takeda
News

KINAXO Extends Collaboration with Takeda

KINAXO Extends Collaboration with Takeda
News

KINAXO Extends Collaboration with Takeda

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "KINAXO Extends Collaboration with Takeda"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

KINAXO Biotechnologies GmbH has announced that it has entered a second collaboration with Takeda Pharmaceutical Company Limited Osaka, Japan. Under the agreement KINAXO will apply its quantitative phosphoproteomics technology PhosphoScout ® to assist in research of drugs under development at Takeda. This will allow Takeda to take early educated decisions on drug efficacy and safety. Financial details of the agreement were not disclosed.

PhosphoScout® enables quantitative analysis of cellular phosphoproteomes on a global scale. Since signal transmission in eukaryotic cells is mainly regulated by reversible protein phosphorylation, comprehensive analysis of phosphoproteome modulation in response to drug treatment provide valuable insights into a drug’s mode of action.

Furthermore, PhosphoScout® can identify differentially regulated phosphorylation sites in vivo that may serve as pharmacodynamic or drug response biomarkers in clinical trials.

PhosphoScout® utilizes mass spectrometry methods enabling unbiased quantification of approx. 15,000 phosphorylation sites in a single experiment. Proprietary bioinformatic software tools are applied to visualize the drug’s effects on cellular signal transduction pathway and help identify phospho-protein biomarkers.

Dr. Andreas Jenne, KINAXO’s CEO said: “We are very pleased to continue our collaboration with Takeda, a world leading healthcare company, and look forward to supporting Takeda’s efforts in developing drugs. This collaboration once again demonstrates the power of our PhosphoScout® platform in drug discovery and development.”

Advertisement